Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) insider John Paolini sold 18,413 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $93.39, for a total value of $1,719,590.07. Following the transaction, the insider owned 69,922 shares of the company’s stock, valued at $6,530,015.58. The trade was a 20.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Price Performance
Shares of KNSA stock opened at $96.11 on Thursday. The stock has a market cap of $7.50 billion, a PE ratio of 73.93 and a beta of 0.07. The stock has a 50-day moving average of $79.99 and a 200-day moving average of $60.85. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $98.48.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The business had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.
Key Kiniksa Pharmaceuticals International News
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Positive Sentiment: Zacks identified KNSA as a strong momentum stock, supporting the view that recent trading and performance trends remain favorable. The company’s latest reported quarterly results also beat analyst expectations for both earnings and revenue. Zacks momentum article
- Negative Sentiment: CEO Sanj Patel and other senior insiders, including the CFO, COO, CAO and John Paolini, disclosed substantial stock sales. Such selling can raise concerns about insider confidence or add selling pressure, although the reported transactions were conducted under pre-arranged Rule 10b5-1 plans. CEO SEC filing Insider sale report
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on KNSA shares. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Canaccord Genuity Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. The Goldman Sachs Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average target price of $100.57.
View Our Latest Stock Analysis on KNSA
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
Several institutional investors have recently modified their holdings of KNSA. Bank of America Corp DE grew its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the period. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after purchasing an additional 421,347 shares in the last quarter. Janus Henderson Group PLC increased its stake in Kiniksa Pharmaceuticals International by 213.5% during the 1st quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after purchasing an additional 327,595 shares in the last quarter. Spruce Street Capital LP raised its holdings in Kiniksa Pharmaceuticals International by 75.0% during the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after buying an additional 326,081 shares during the period. Finally, Pictet Asset Management Holding SA raised its holdings in Kiniksa Pharmaceuticals International by 41.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after buying an additional 251,578 shares during the period. Institutional investors own 53.95% of the company’s stock.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Featured Articles
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
